uniQure (NASDAQ:QURE) Given “Neutral” Rating at Mizuho

Mizuho restated their neutral rating on shares of uniQure (NASDAQ:QURE) in a research report report published on Tuesday morning, MarketBeat reports. They currently have a $12.00 target price on the biotechnology company’s stock, down from their prior target price of $33.00.

A number of other analysts also recently issued reports on QURE. Chardan Capital lowered their price target on uniQure from $53.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank Of Canada downgraded shares of uniQure from a “moderate buy” rating to a “hold” rating and set a $11.00 target price on the stock. in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday, February 10th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research note on Monday. Finally, Stifel Nicolaus set a $14.00 target price on uniQure in a research report on Monday. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.33.

uniQure Stock Down 14.0%

Shares of NASDAQ:QURE opened at $9.03 on Tuesday. The company has a market cap of $562.48 million, a price-to-earnings ratio of -2.62 and a beta of 0.73. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The company has a 50-day moving average price of $22.86 and a 200 day moving average price of $29.72.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 230.98% and a negative net margin of 1,236.00%. As a group, equities research analysts predict that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 12,378 shares of uniQure stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the sale, the chief executive officer directly owned 639,076 shares of the company’s stock, valued at $15,248,353.36. This represents a 1.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,598 shares of company stock valued at $1,248,588 in the last quarter. Corporate insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. bought a new position in shares of uniQure during the 2nd quarter worth $29,217,000. State Street Corp increased its position in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the period. Finally, MPM Bioimpact LLC purchased a new stake in shares of uniQure in the 4th quarter worth approximately $33,062,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.